Related references
Note: Only part of the references are listed.Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution
I. Glezerman et al.
CLINICAL NEPHROLOGY (2011)
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
Xiaolei Zhu et al.
ACTA ONCOLOGICA (2009)
Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia
Sarah A. Holstein et al.
LEUKEMIA RESEARCH (2009)
Lung Cancer and Renal Insufficiency: Prevalence and Anticancer Drug Issues
Vincent Launay-Vacher et al.
LUNG (2009)
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib
Guillaume Bollee et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis
Andrew B. Avarbock et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Partial Fanconi syndrome induced by imatinib therapy: A novel cause of urinary phosphate loss
Helene Francois et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2008)
Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care
Vincent Launay-Vacher et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia
Leslie A. Andritsos et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review
Bertrand Coiffier et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A Preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib
Tejas V. Patel et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Glomerular disease related to anti-VEGF therapy
M. Barry Stokes et al.
KIDNEY INTERNATIONAL (2008)
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
Shenhong Wu et al.
LANCET ONCOLOGY (2008)
Pathogenesis and treatment of renal failure in multiple myeloma
M. A. Dimopoulos et al.
LEUKEMIA (2008)
VEGF inhibition and renal thrombotic microangiopathy
Vera Eremina et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Ifosfamide induces acute renal failure via inhibition of the thioredoxin reductase activity
Jinsong Zhang et al.
FREE RADICAL BIOLOGY AND MEDICINE (2007)
Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma
Heinz Ludwig et al.
HAEMATOLOGICA (2007)
Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome
E. Kapiteijn et al.
ANNALS OF ONCOLOGY (2007)
Angiogenesis inhibitor therapies: Focus on kidney toxicity and hypertension
Hassane Izzedine et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2007)
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma
Robert A. Kyle et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Thrombotic microangiopathy and anti-VEGF agents
Hassane Izzedine et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis
Xiaolei Zhu et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2007)
International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency
Stuart M. Lichtman et al.
EUROPEAN JOURNAL OF CANCER (2007)
Review: Side effects of approved molecular targeted therapies in solid cancers
Christian Widakowich et al.
ONCOLOGIST (2007)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: A review of some recent research
Badreldin H. Ali et al.
FOOD AND CHEMICAL TOXICOLOGY (2006)
Acute renal failure associated with gefitinib therapy
Hsiang-Lin Wan et al.
LUNG (2006)
Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer
Ganesh V. Raj et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Understanding and managing methotrexate nephrotoxicity
Brigitte C. Widemann et al.
ONCOLOGIST (2006)
Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer
Stacy S. Shord et al.
ANTI-CANCER DRUGS (2006)
Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy
DA Hutcherson et al.
PHARMACOTHERAPY (2006)
Clinical experience with denileukin diftitox (ONTAK)
F Foss
SEMINARS IN ONCOLOGY (2006)
Drug-associated renal dysfunction and injury
D Choudhury et al.
NATURE CLINICAL PRACTICE NEPHROLOGY (2006)
An anaphylactoid reaction from amifostine
Alexander Lin
RADIOTHERAPY AND ONCOLOGY (2006)
Ibandronate for the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure: Case reports
Dirk Henrich et al.
ACTA HAEMATOLOGICA (2006)
Acute renal failure secondary to imatinib mesylate treatment in prostate cancer
JR Foringer et al.
ANNALS OF PHARMACOTHERAPY (2005)
Taurine protects against methotrexate-induced toxicity and inhibits leukocyte death
M Çetiner et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2005)
Magnesium depletion enhances cisplatin-induced nephrotoxicity
H Lajer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Effects of lycopene against cisplatin-induced nephrotoxicity and oxidative stress in rats
A Atessahin et al.
TOXICOLOGY (2005)
Protective effects of capsaicin against cisplatin-induced nephrotoxicity in rats
Y Shimeda et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2005)
Cetuximab therapy and symptomatic hypomagnesemia
D Schrag et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats
T Uehara et al.
ARCHIVES OF TOXICOLOGY (2005)
Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation
Y Kawai et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2005)
Renal toxicity of Oxaliplatin
J Labaye et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2005)
A tubule cell model for ifosfamide nephrotoxicity
K Aleksa et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2005)
Theophylline for prevention of contrast-induced nephropathy - A systematic review and meta-analysis
SM Bagshaw et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Investigation of the role of hyperbaric oxygen therapy in cisplatin-induced nephrotoxicity in rats
E Atasoyu et al.
ARCHIVES OF TOXICOLOGY (2005)
Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate:: True association or mere coincidence?
Z Al Aly et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2005)
Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity
N Asna et al.
LIFE SCIENCES (2005)
Cisplatin nephrotoxicity is mediated by deoxyribonuclease I
AG Basnakian et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway
YJ Wu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
KD Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation
N Leung et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2005)
Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats
M Naziroglu et al.
TOXICOLOGY (2004)
Erythropoietin protects against ischaemic acute renal injury
DA Vesey et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2004)
Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-α
G Ramesh et al.
KIDNEY INTERNATIONAL (2004)
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure
P Tosi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2004)
Mechanisms of naringenin-induced apoptotic cascade in cancer cells:: Involvement of estrogen receptor α and β signalling
P Totta et al.
IUBMB LIFE (2004)
Melatonin attenuates ifosfamide-induced Fanconi syndrome in rats
G Sener et al.
JOURNAL OF PINEAL RESEARCH (2004)
Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity
C Marzano et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2004)
Case 1. Nephrotic syndrome associated with gefitinib therapy
R Kumasaka et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Gemcitabine-associated thrombotic microangiopathy
BD Humphreys et al.
CANCER (2004)
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
DH Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma - Incidence, treatment, and outcome
BC Widemann et al.
CANCER (2004)
End-stage renal disease after high-dose carboplatinum in preparation of autologous stem cell transplantation
L Butani et al.
PEDIATRIC TRANSPLANTATION (2003)
Chronic ifosfamide nephrotoxicity in children
R Skinner
MEDICAL AND PEDIATRIC ONCOLOGY (2003)
Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial
JT Santoso et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
Toxic acute tubular necrosis following treatment with zoledronate (Zometa)
GS Markowitz et al.
KIDNEY INTERNATIONAL (2003)
The effects of oral glutamine on cisplatin-induced nephrotoxicity in rats
LD Mora et al.
PHARMACOLOGICAL RESEARCH (2003)
Metabolism of cisplatin to a nephrotoxin in proximal tubule cells
DM Townsend et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2003)
A case of acute tubular necrosis due to oxaliplatin
G Pinotti et al.
ANNALS OF ONCOLOGY (2002)
Gemcitabine-associated hemolytic-uremic syndrome
RB Walter et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2002)
Alpha-interferon-associated thrombotic microangiopathy - A clinicopathologic study of 8 patients and review of the literature
J Zuber et al.
MEDICINE (2002)
Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C
RA Willson
JOURNAL OF CLINICAL GASTROENTEROLOGY (2002)
Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571
C Kitiyakara et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2002)
Oral administration of sodium selenite minimizes cisplatin toxicity on proximal tubules of rats
SMR Camargo et al.
BIOLOGICAL TRACE ELEMENT RESEARCH (2001)
Young age and the risk for ifosfamide-induced nephrotoxicity: a critical review of two opposing studies
K Aleksa et al.
PEDIATRIC NEPHROLOGY (2001)
Ifosfamide nephrotoxicity in pediatric cancer patients
BS Lee et al.
PEDIATRIC NEPHROLOGY (2001)
Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant
SM Devine et al.
BONE MARROW TRANSPLANTATION (2001)
A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis
SC Goldman et al.
BLOOD (2001)
Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats
M Hara et al.
JOURNAL OF PINEAL RESEARCH (2001)
Anticancer drug-induced kidney disorders - Incidence, prevention and management
PE Kintzel
DRUG SAFETY (2001)
Share Paper
